The partnership, backed by investors Population Health Partners and ARCH Venture Partners, includes an initial $75.89 million in upfront payments and equity. Beyond this, Haisco stands to collect up to $1.46 billion tied to development, regulatory, and commercial milestones, alongside tiered royalties on future sales. The asset, which recently secured an Investigational New Drug approval in China, targets type 2 inflammatory conditions and has shown positive safety and efficacy data in early studies.

Moving away from traditional licensing models, Haisco has opted for a "Newco" structure with Sentivera. This approach aims to secure deeper strategic alignment between the Chinese developer and its US partners. For Haisco, the deal serves as a cornerstone of its international strategy to transition from regional player to global pharmaceutical contributor. With over 70 programs currently in its R&D pipeline, the company is leveraging this collaboration to accelerate the clinical translation of its immunology portfolio while establishing a sustainable revenue stream in Western markets.